176 related articles for article (PubMed ID: 23228943)
21. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
22. Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings.
Urtishak KA; Robinson BW; Rappaport EF; Sarezky MD; Biegel JA; Nichols KE; Wilmoth DM; Wang LS; Stern JW; Felix CA
Pediatr Blood Cancer; 2016 Jul; 63(7):1175-80. PubMed ID: 26999444
[TBL] [Abstract][Full Text] [Related]
23. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
24. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
25. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
26. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
[TBL] [Abstract][Full Text] [Related]
27. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
28. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.
Ahlmann M; Meyer C; Marschalek R; Burkhardt B; Koehler G; Klapper W; Juergens H; Rossig C
Eur J Haematol; 2014 Oct; 93(4):349-53. PubMed ID: 24635731
[TBL] [Abstract][Full Text] [Related]
29. A pediatric B lineage leukemia with coincident MYC and MLL translocations.
Meeker ND; Cherry AM; Bangs CD; Frazer JK
J Pediatr Hematol Oncol; 2011 Mar; 33(2):158-60. PubMed ID: 20829716
[TBL] [Abstract][Full Text] [Related]
30. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell.
Chen MB; Shen WX; Yang Y; Wu XY; Gu JH; Lu PH
J Cell Physiol; 2011 Jul; 226(7):1915-25. PubMed ID: 21506122
[TBL] [Abstract][Full Text] [Related]
31. AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C.
Vucicevic L; Misirkic M; Janjetovic K; Harhaji-Trajkovic L; Prica M; Stevanovic D; Isenovic E; Sudar E; Sumarac-Dumanovic M; Micic D; Trajkovic V
Biochem Pharmacol; 2009 Jun; 77(11):1684-93. PubMed ID: 19428322
[TBL] [Abstract][Full Text] [Related]
32. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
33. MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma.
Mater DV; Goodman BK; Wang E; Gaca AM; Wechsler DS
J Pediatr Hematol Oncol; 2012 Apr; 34(3):e120-3. PubMed ID: 22052166
[TBL] [Abstract][Full Text] [Related]
34. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
35. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
[TBL] [Abstract][Full Text] [Related]
36. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Benito JM; Godfrey L; Kojima K; Hogdal L; Wunderlich M; Geng H; Marzo I; Harutyunyan KG; Golfman L; North P; Kerry J; Ballabio E; Chonghaile TN; Gonzalo O; Qiu Y; Jeremias I; Debose L; O'Brien E; Ma H; Zhou P; Jacamo R; Park E; Coombes KR; Zhang N; Thomas DA; O'Brien S; Kantarjian HM; Leverson JD; Kornblau SM; Andreeff M; Müschen M; Zweidler-McKay PA; Mulloy JC; Letai A; Milne TA; Konopleva M
Cell Rep; 2015 Dec; 13(12):2715-27. PubMed ID: 26711339
[TBL] [Abstract][Full Text] [Related]
37. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
38. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in
Wölfl M; Rasche M; Eyrich M; Schmid R; Reinhardt D; Schlegel PG
Blood Adv; 2018 Jun; 2(12):1382-1385. PubMed ID: 29898879
[TBL] [Abstract][Full Text] [Related]
39. Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1.
Jang JH; Lee TJ; Yang ES; Min do S; Kim YH; Kim SH; Choi YH; Park JW; Choi KS; Kwon TK
Exp Cell Res; 2010 Aug; 316(13):2194-203. PubMed ID: 20451517
[TBL] [Abstract][Full Text] [Related]
40. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway.
Shin SM; Cho IJ; Kim SG
Mol Pharmacol; 2009 Oct; 76(4):884-95. PubMed ID: 19620254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
